➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKinsey
Express Scripts
McKesson
Mallinckrodt

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

ZINGO Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Zingo patents expire, and what generic alternatives are available?

Zingo is a drug marketed by Powder Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has sixteen patent family members in ten countries.

The generic ingredient in ZINGO is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

Summary for ZINGO
International Patents:16
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 5
Formulation / Manufacturing:see details
DailyMed Link:ZINGO at DailyMed
Drug patent expirations by year for ZINGO
Pharmacology for ZINGO

US Patents and Regulatory Information for ZINGO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Powder Pharms ZINGO lidocaine hydrochloride SYSTEM;INTRADERMAL 022114-001 Aug 16, 2007 RX No No   Start Trial   Start Trial   Start Trial
Powder Pharms ZINGO lidocaine hydrochloride SYSTEM;INTRADERMAL 022114-001 Aug 16, 2007 RX No No   Start Trial   Start Trial   Start Trial
Powder Pharms ZINGO lidocaine hydrochloride SYSTEM;INTRADERMAL 022114-001 Aug 16, 2007 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZINGO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Powder Pharms ZINGO lidocaine hydrochloride SYSTEM;INTRADERMAL 022114-001 Aug 16, 2007   Start Trial   Start Trial
Powder Pharms ZINGO lidocaine hydrochloride SYSTEM;INTRADERMAL 022114-001 Aug 16, 2007   Start Trial   Start Trial
Powder Pharms ZINGO lidocaine hydrochloride SYSTEM;INTRADERMAL 022114-001 Aug 16, 2007   Start Trial   Start Trial
Powder Pharms ZINGO lidocaine hydrochloride SYSTEM;INTRADERMAL 022114-001 Aug 16, 2007   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKinsey
Express Scripts
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.